Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12605000366651
ACTRN12605000366651
Active, not recruiting
Phase 3

A double-blind, dose-ranging study to determine the optimal dose of oral morphine or oxycodone needed to treat breakthrough pain for people on regular opioid in the palliative care setting

Repatriation General Hospital0 sites138 target enrollmentSeptember 13, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreakthrough PainAlternative and Complementary Medicine - Pain management

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Breakthrough Pain
Sponsor
Repatriation General Hospital
Enrollment
138
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 13, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Repatriation General Hospital

Eligibility Criteria

Inclusion Criteria

  • •English speaking, AKPS performance status of 100 to 30, Calculated creatinine clearance of \> 20 ml/minVenous blood sample for creatinine level, Stable background oral opioid for the previous 4 days, Successfully using breakthrough doses, Physically able to complete study measures.

Exclusion Criteria

  • •Confusion, Uncontrolled nausea or vomiting, Suspected gastro\-intestinal obstruction, Known or suspected hypersensitivity to morphine or oxycodone, Past history of substance misuse, Declines to participate.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A dose finding study of OligoG in patients with CF.Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-000378-30-DEAlgiPharma AS168
Active, not recruiting
Phase 1
A dose finding study of OligoG in patients with CF.Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-000378-30-PLAlgiPharma AS180
Active, not recruiting
Phase 1
A dose finding study of OligoG in patients with CF.Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-000378-30-ATAlgiPharma AS168
Active, not recruiting
Phase 1
A dose finding study of OligoG in patients with CF.Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-000378-30-GBAlgiPharma AS168
Active, not recruiting
Phase 1
A dose finding study of OligoG in patients with CF.Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-000378-30-IEAlgiPharma AS168